Navigation Links
TauTaTis Discovers Potent Inhibitor of Parkinson's Disease Gene Activity
Date:3/16/2009

JACKSONVILLE, Fla., March 16 /PRNewswire/ -- TauTaTis, Inc. announces that its lead compound for inhibition of tau protein pathology, the specific neurodegenerative process in Alzheimer's Disease, has been recognized as the most potent inhibitor of the activity of the Parkinson's Disease gene LRRK2 reported to date. Mutations of this gene are believed to increase its activity, and are the most genetic frequent cause of Parkinson's Disease.

TauTaTis' lead compound is a proprietary small molecule that has shown good tolerability in small animals with chronic oral dosing, and enters the brain at therapeutically relevant concentrations. It is therefore a promising development candidate for two of the most important degenerative neurological conditions of the aged population.

Parkinson's Disease is the second most common progressive neurodegenerative disease after Alzheimer's Disease. About 1 million patients are living with Parkinson's Disease in the US. Symptoms progress from tremor to progressive loss of movement control and rigidity. In some instances the disease may progress further to dementia, sometimes involving the type of neurodegeneration seen in Alzheimer's Disease. Most cases are not obviously linked to genetic mutations, but about 10% of the cases are inherited. Several genes have been identified as drivers of the disease, with LRRK2 being the most prominent.

Current treatments of Parkinson's Disease help to offset symptoms for a limited period of time, but do not alter the prognosis of the disease, which would require to stop the loss of nerve cells, a feat not accomplished in any neurodegenerative disorder to date.

"LRRK2 is one of the most promising targets to fundamentally address a vexing disorder that has not seen any improvements of the therapeutic standard in a long time. This exciting discovery significantly broadens the scope of our lead development program, which targets the biological basis of neurodegenerative disease. It also suggests that there may be underlying commonalities in seemingly disparate disorders. Based on encouraging data for our lead compound in several therapeutic areas the company will seek to access several translational grant mechanisms for further development. If successful, funds of up to $2.5 million could become available from such sources by summer or fall of 2009," comments Dr. Hanno Roder, Founder, Chairman and CEO of TauTaTis, Inc.

TauTaTis, Inc. (http://www.tautatis.com) is an early stage company centered on the preclinical and clinical development of compounds, which directly interfere with aberrant biochemical processes in degenerating nerve cells. Its lead compound is the result of an optimization process conducted over more than a decade involving an integrated process of research into disease mechanisms, extensive target profiling, model development and medicinal chemistry.

    Contact:
    Dr. Hanno Roder
    TauTaTis, Inc.
    Tel.:  +1-904-220-1283
    Fax:  +1-904-221-6013
    E-mail:  hanno.roder@tautatis.net

    URL:  www.tautatis.net


'/>"/>
SOURCE TauTaTis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor
2. deCODE Discovers Common Genetic Variations Contributing to Low Bone Mineral Density and Risk of Osteoporosis
3. deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer
4. deCODE Discovers Gene Variants that May Help to Distribute the Work of Evolution between Men and Women
5. Medical Breakthrough ... Doctor Discovers Penetrating Carrier That Eradicates Fungus
6. Improved Cryopreservation Outcomes in Potential $100B Tissue Engineering Market Enabled by BioLife Solutions CryoStor(TM)
7. Researchers discover a potential on-off switch for nanoelectronics
8. Research highlights potential for improved solar cells
9. Accidental discovery has potential for new applications in packaging
10. Historic Seed Delivery Made in Illinois for First New Soybean Varieties With the Greater Yield Potential of Roundup Ready 2 Yield(TM)
11. XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
(Date:6/24/2016)... Raleigh, NC (PRWEB) , ... June 24, 2016 , ... ... find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings ... here to read it now. , Diagnostic biomarkers are signposts in the blood, ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):